| MedWatch - The FDA Safety Information and Adverse Event Reporting Program | | | TOPIC: Suave 24-Hour Protection Aerosol Antiperspirant Powder and Suave 24-Hour Protection Aerosol Antiperspirant Fresh by Unilever: Recall - Due to Presence of Slightly Elevated Levels of Benzene AUDIENCE: Consumer, Health Professional ISSUE: Unilever is recalling two Suave 24-Hour Protection Aerosol Antiperspirants because an internal review showed slightly elevated levels of benzene in some product samples. While benzene is not an ingredient in any of the recalled products, the review showed that unexpected levels of benzene came from the propellant that sprays the product out of the can. Based on an independent health hazard evaluation, daily exposure to benzene in the recalled products at the levels detected in testing would not be expected to cause adverse health consequences. For more information about this recall, click on the red button Read Recall below. BACKGROUND: Benzene is classified as a human carcinogen. Exposure to benzene can occur by inhalation, orally, and through the skin; it can result in cancers including leukemia and blood cancer of the bone marrow and blood disorders which can be life threatening. RECOMMENDATIONS: - Consumers should stop using and appropriately discard the affected Suave 24-Hour Protection Aerosol Antiperspirant products.
- Consumers should contact their physician or healthcare provider if they have any questions or have experienced any problems that may be related to using these aerosol antiperspirant products.
- Consumers with questions regarding this recall can contact the company.
| | Consumers and health professionals are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: - Complete and submit the report online.
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form, or submit by fax to 1-800-FDA-0178.
| | | |
No comments:
Post a Comment